NT_1170x120_1-11-18

Brent Saunders

AbbVie to acquire Allergan

AbbVie to acquire Allergan

NORTH CHICAGO, Ill. — AbbVie  and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. (PRNewsfoto/AbbVie) “This is a

Allergan unveils new digital hub Spotlyte

Allergan unveils new digital hub Spotlyte

DUBLIN — Allergan announced the launch of Spotlyte – an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Through well-researched content, product reviews and insider profiles, together with the latest beauty news and trends, the site functions as a holistic and informative lens into these worlds.

Allergan COO to become Amneal CEO

Allergan COO to become Amneal CEO

NEW YORK — Merger partners Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have tabbed Robert Stewart, executive vice president and chief operating officer of Allergan plc, to lead the combined company. Plans call for Stewart to join Amneal as president effective Jan. 25. After Amneal and Impax finalize their merger, announced in mid-October, he will

Allergan announces pair of biopharma acquisitions

Allergan announces pair of biopharma acquisitions

DUBLIN, Ireland — Chalk up three acquisitions for Allergan plc in less than a week. On Tuesday, Allergan said it plans to purchase clinical-stage biopharmaceutical company Tobira Therapeutics Inc. in an agreement valued at up to $1.695 billion. South San Francisco-based Tobira focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and

Allergan to acquire Vitae Pharmaceuticals

Allergan to acquire Vitae Pharmaceuticals

DUBLIN, Ireland — Allergan plc plans to buy clinical-stage biotech firm Vitae Pharmaceuticals Inc. in a cash deal valued at $639 million. Allergan said the acquisition will bolster its dermatology product pipeline with the addition of VTP-43742, a Phase 2 orally active RORγt inhibitor for the potential treatment of psoriasis and other autoimmune disorders. The

Allergan sells Anda to Teva for $500 million

Allergan sells Anda to Teva for $500 million

NEW YORK — Another large deal has been struck between Allergan plc and Teva Pharmaceutical Industries Ltd. The companies on Wednesday announced the sale of Allergan’s Anda Inc. distribution business to Teva for $500 million. That came a day after they reported the close of Teva’s $39 billion acquisition of the Allergan’s legacy Actavis generics

Teva, Allergan complete $39 billion generics deal

Teva, Allergan complete $39 billion generics deal

NEW YORK — Teva Pharmaceutical Industries Ltd. has closed its acquisition of the Allergan plc generics business. The companies said Tuesday that under the deal, announced last July, Allergan receives $33.4 billion in cash and 100.3 million shares of Teva stock, valued at $5.4 billion based on the opening price of $53.39 for Teva shares

Pfizer, Allergan merger aborted

NEW YORK — Pfizer Inc. and Allergan PLC have, by mutual agreement, terminated their planned merger. Pfizer management attributed the decision to new tax rules issued by the Treasury Department that are specifically intended to make such combinations less ­attractive. Under the proposed merger, Pfizer would have shifted its corporate address — but not its

Pfizer names post-Allergan merger exec team

Pfizer names post-Allergan merger exec team

NEW YORK — Pfizer Inc. has announced the executive leadership team following the completion of its acquisition of Allergan plc. The pharmaceutical giant said Monday that, as announced previously, Allergan chief executive officer Brent Saunders will become president and chief operating officer of the merged company, overseeing Pfizer and Allergan’s combined commercial businesses, manufacturing and